title: Reporting bias in trials of volume resuscitation with hydroxyethyl starch.
abstract: The possibility of renal damage by hydroxyethyl starch has become the focus of intensive dispute based on the findings of published large trials. The aim of this narrative review is to analyze outcome reporting bias in the literature on volume resuscitation, focusing on selective outcome reporting in published randomized and observational trials with "modern" hydroxyethyl starch as therapeutic intervention. Three recent publications claimed to confirm renal safety of hydroxyethyl starch 130/0.4 for indications in severe sepsis, trauma, and critical illness, respectively. Selective outcome reporting was identified in these studies including underreporting of side effects and change of primary study outcomes. In conclusion, selective outcome reporting bias is identified in recent publications of clinical trials on volume resuscitation with HES.
authors.affiliation: Academic Teaching Department of Internal Medicine, Central Hospital of Bozen/Bolzano, Lorenz-Böhler-Street 5, 39100, Bozen/Bolzano (BZ), Italy, christian.wiedermann@asbz.it.
authors.forename: Christian J
authors.initials: CJ
authors.lastname: Wiedermann
mesh_terms: D058186:Acute Kidney Injury / Q000401:mortality*; D015982:Bias; D004282:Documentation / Q000706:statistics & numerical data*; D005440:Fluid Therapy / Q000401:mortality*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use*; D020896:Hypovolemia / Q000401:mortality* / Q000473:pathology*; D015994:Incidence; D010952:Plasma Substitutes / Q000627:therapeutic use; D012151:Resuscitation / Q000401:mortality*; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes